1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Denovo takes on failed Lilly cancer drug

 
• By Eleanor Malone

San Diego firm Denovo Biopharma is hoping to breathe fresh life into a drug written off by Lilly after it failed late-stage trials. The privately held biotech company believes that its technology for discovering biomarkers using archived clinical trial samples may enable it to identify subsets of patients who are more likely to respond to treatment with the drug, enzastaurin. It has acquired all rights to the drug worldwide.

San Diego firm Denovo Biopharma is hoping to breathe fresh life into a drug written off by Lilly after it failed late-stage trials. The privately held biotech company believes that its technology for discovering biomarkers using archived clinical trial samples may enable it to identify subsets of patients who are more likely to respond to treatment with the drug, enzastaurin. It has acquired all rights to the drug worldwide.

Lilly had developed enzastaurin to treat diffuse large B-cell lymphoma (DLBCL) but after promising Phase II results in the DLBCL induction setting it failed to meet the primary endpoint in the maintenance setting in Phase III (

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.